[PRESS RELEASE ] – NEW YORK and SAVONA, Italy, Jan. 22, 2026 – Tilray Medical, a division of Tilray Brands Inc. ("Tilray") and a global leader in medical cannabis, empowering the therapeutic alliance between patients and health care practitioners to make informed individualized health decisions, announced a strategic update to its medical cannabis operations in Italy with the launch of Tilray Medical Italia, the new name of the entity previously known as FL Group.
The transition to Tilray Medical Italia reflects the company’s continued commitment to building a unified, scalable medical cannabis platform across Europe, while strengthening its presence in one of the region’s most important regulated medical markets.
Tilray Medical Italia is expanding its footprint in Italy through a growing portfolio of medical cannabis products authorized by the Italian Ministry of Health and supported by a partnership with Molteni Farmaceutici, one of Italy’s leading pharmaceutical companies with deep experience serving hospitals, physicians and pharmacies across the country.
Rajnish Ohri, president of International at Tilray Brands, said, “Italy remains a strategically important market for Tilray Medical as we continue to build a leading, regulated medical cannabis platform across Europe. The launch of Tilray Medical Italia strengthens our local presence, aligns our operations under a single global medical brand, and reinforces our long-term commitment to supporting patients, physicians and health care systems with high-quality, authorized medical cannabis products.”
Strengthening a Regulated Medical Cannabis Platform in Italy
Tilray Medical Italia operates within Italy’s established medical cannabis framework, supplying products authorized by the Ministry of Health and distributed through hospital and pharmacy channels in accordance with national regulations. The company’s Italian operations are supported by Tilray’s broader European medical infrastructure, including pharmaceutical-grade cultivation, manufacturing, quality assurance and regulatory expertise developed across multiple federally legal medical cannabis markets.
Through its partnership with Molteni, Tilray Medical Italia continues to support physician education, responsible prescribing and patient access, while maintaining rigorous standards for product quality, safety and compliance.
“Our collaboration with Molteni enables us to effectively serve the Italian medical community while maintaining the highest standards expected in a regulated pharmaceutical environment,”
Ohri said. “As demand for medical cannabis continues to evolve, Tilray Medical Italia is well-positioned to responsibly support the market’s development.”
Tilray Medical Italia supplies pharmaceutical-grade medical cannabis to pharmacies throughout Italy. Products are available by prescription in accordance with Italian Ministry of Health regulations.
To date, Tilray Medical Italia’s product portfolio includes:
Medical cannabis flower:
- THC 25%
- THC 18%
- THC 9% / CBD 9%
Medical cannabis oil:
- THC10:CBD10 (25ml)
- THC10:CBD10 (100ml)
- THC25:CBD25 (25ml)
- THC5:CBD20 (25ml)
- THC20:CBD6 (25ml)
- THC25 (25ml)
These offerings deliver a comprehensive selection of EU-GMP certified therapies designed to meet diverse patient needs.
Part of Tilray Medical’s Broader European Strategy
The launch of Tilray Medical Italia follows Tilray’s broader strategy to unify its medical cannabis operations under a single global medical business/brand, leveraging shared expertise across Europe and other international markets. Tilray Medical has served more than 20 countries with established medical cannabis programs, working closely with regulators, health care professionals and research partners to advance evidence-based cannabinoid therapies.
Tilray Brands remains focused on disciplined, compliant growth in regulated medical markets, with patient safety, scientific integrity and long-term sustainability at the core of its approach.
